Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2021-06-23 Regulatory Filings
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Oslo Børs – Resolution of transfer of listing from Euronext Growth to Oslo Børs – Gentian Diagnostics ASA
Regulatory Filings Classification · 95% confidence The document text explicitly announces a 'Resolution of transfer of listing from Euronext Growth to Oslo Børs' for Gentian Diagnostics ASA. This action—moving a stock listing from one exchange segment to another—is a significant corporate event related to the company's stock market status. It does not fit the definitions for Annual Reports (10-K), Earnings Releases (ER), Dividend Notices (DIV), or standard regulatory filings (RNS). It is most closely related to major corporate structure or market status changes. Since there is no specific code for 'Listing Transfer Announcement,' and it is not a financing event (CAP), delisting (DLST), or share transaction (POS), the most appropriate general category for a significant, non-standard corporate announcement that affects market status is the general Regulatory Filings category (RNS), as it is a formal notice to the market about a change in trading venue.
2021-06-23 English
Gentian Diagnostics: Invitation to virtual presentation at 24 June
Report Publication Announcement Classification · 99% confidence The document is a short announcement inviting stakeholders to a virtual presentation scheduled for June 24th. The purpose of this presentation is explicitly stated as being 'in relation with the company’s updated investor presentation and new long-term ambition'. Since the document itself is an invitation to an event where an Investor Presentation (IP) will be discussed/released, and given its short length (1521 chars), it functions as an announcement about upcoming investor material rather than the presentation itself. However, the core subject matter relates directly to investor communication regarding strategy and ambition, which aligns closely with the Investor Presentation (IP) category. Since it is an invitation to an event where the IP will be presented, classifying it as an Investor Presentation (IP) is the most relevant content classification, although it could arguably be an RPA if the focus was purely on the announcement mechanism. Given the context of 'updated investor presentation' being the subject, IP is the best fit.
2021-06-18 English
Gentian Diagnostics: A long-term revenue ambition of NOK 1 billion from a portfolio of high-impact diagnostic tests
Investor Presentation Classification · 99% confidence The document is explicitly titled "Investor presentation June 2021" and contains extensive slides detailing company strategy, management team biographies, product portfolio, market analysis (TAM/SAM), historical revenue, growth ambitions (NOK 1bn in 5-7 years), and a roadmap of future milestones. This structure and content are characteristic of an Investor Presentation (IP), which is designed to communicate financial performance, strategy, and outlook to current and potential investors.
2021-06-18 English
Gentian Diagnostics: A long-term revenue ambition of NOK 1 billion from a portfolio of high-impact diagnostic tests
Earnings Release Classification · 99% confidence The document text explicitly states, "In an updated investor presentation, the company outlines the market potential and roadmap for its portfolio..." and concludes with, "For further information, please refer to the attached investor presentation or contact:". This indicates the document itself is likely a press release or announcement *about* an investor presentation, or it is the presentation itself being distributed. Given the content details strategic pillars, revenue ambitions, and product roadmaps, it strongly aligns with the content of an Investor Presentation (IP). The document length (4562 chars) is substantial enough to be the presentation summary or the presentation itself, rather than just a brief RPA announcement. FY 2020
2021-06-18 English
Application for transfer of shares admitted to trading on Euronext Growth to to Oslo Børs
Delisting Announcement Classification · 99% confidence The document text explicitly states an 'Application for transfer of shares admitted to trading on Euronext Growth to Oslo Børs'. This concerns the listing venue of the company's shares, which is a significant corporate action related to trading status. While it is a regulatory announcement, it does not fit the specific definitions for Delisting (DLST) as it is a transfer, nor does it fit Capital/Financing (CAP) or Share Issue (SHA). Since it is a specific regulatory notice about the listing venue, and given the available codes, the most appropriate general category for a specific, non-standard regulatory announcement that doesn't fit the primary financial/governance categories is Regulatory Filings (RNS). The document is very short (327 chars) and functions as a notification of an application.
2021-05-07 English
Gentian Diagnostics ASA – Application for admission to trading on Oslo Børs
Delisting Announcement Classification · 99% confidence The document is a short announcement (953 characters) from Gentian Diagnostics ASA regarding its application to transfer its listing from Euronext Growth to the main board of Oslo Børs. This is a specific corporate action related to stock exchange listing/trading status. It is not an Annual Report (10-K), Earnings Release (ER), or a standard dividend notice. Since it announces a change related to the company's listing status, it is most closely related to corporate structure/financing changes or a general regulatory announcement. Given the options, it doesn't fit perfectly into CAP (Capital/Financing Update) as it's a listing transfer, not fundraising. It is a specific corporate announcement that doesn't map cleanly to the defined categories like AGM, ER, or DIV. Therefore, the most appropriate fallback category for a specific, non-standard regulatory/exchange announcement is Regulatory Filings (RNS).
2021-05-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.